VistaGen Therapeutics, Inc. (VTGN) News

VistaGen Therapeutics, Inc. (VTGN): $3.42

0.10 (-2.84%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add VTGN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#155 of 352

in industry

Filter VTGN News Items

VTGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VTGN News Highlights

  • VTGN's 30 day story count now stands at 2.
  • Over the past 7 days, the trend for VTGN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about VTGN are CNS.

Latest VTGN News From Around the Web

Below are the latest news stories about VISTAGEN THERAPEUTICS INC that investors may wish to consider to help them evaluate VTGN as an investment opportunity.

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

SOUTH SAN FRANCISCO, Calif., December 27, 2023--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) issued a Notice of Intention to Grant a patent related to the use of AV-101 for the treatment of neuropathic pain. AV-101 is the Company’s investigational oral prodrug of 7-chloro-ky

Yahoo | December 27, 2023

11 Most Promising Psychedelic Stocks According to Hedge Funds

In this piece, we will take a look at the 11 most promising psychedelic stocks according to hedge funds. If you want to skip our overview of the psychedelic industry and the latest news, then you can take a look at the 5 Most Promising Psychedelic Stocks. The ability to use chemicals to alter one’s […]

Yahoo | December 20, 2023

Retail investors are Vistagen Therapeutics, Inc.'s (NASDAQ:VTGN) biggest owners and were rewarded after market cap rose by US$12m last week

Key Insights Significant control over Vistagen Therapeutics by retail investors implies that the general public has...

Yahoo | November 29, 2023

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript November 10, 2023 Operator: Good day, everyone and welcome to today’s Vistagen Fiscal Year 2024 Second Quarter Corporate Update Conference Call. [Operator Instructions] Please note this call is being recorded. I will be standing by if you should need any assistance. It is now my pleasure […]

Yahoo | November 11, 2023

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., November 09, 2023--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2024 second quarter ended September 30, 2023.

Yahoo | November 9, 2023

Vistagen to Present at Stifel 2023 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., November 08, 2023--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that company management will present and host one-on-one meetings at the Stifel 2023 Healthcare Conference taking place November 14 – 15, 2023 at the Lotte New York Palace Hotel in New York City.

Yahoo | November 8, 2023

Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences

SOUTH SAN FRANCISCO, Calif., November 07, 2023--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the Company will present at two upcoming scientific conferences in November.

Yahoo | November 7, 2023

Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023

SOUTH SAN FRANCISCO, Calif., November 06, 2023--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Thursday, November 9, 2023, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to provide a corporate update and report results for its fiscal year 2024 second quarter ended

Yahoo | November 6, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time for another dive into the biggest pre-market stock movers as we list out the top stocks worth watching on Tuesday!

William White on InvestorPlace | October 17, 2023

Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

SOUTH SAN FRANCISCO, Calif., October 05, 2023--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the Company will present and host one-on-one meetings at the Jefferies Biotech CNS/Neuro Summit taking place October 11 – 12, 2023 in New York City, New York.

Yahoo | October 5, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!